Rachael’s broad experience covers the full range of issues that arise for health care companies in life sciences, most prominently with entities involved in the compounding of drugs across both the human and animal health spheres. A wide variety of health care entities, including telehealth platforms, drug distributors, physician and veterinary practices, on line pharmacy and prescription management services, as well as pharmacies (commercial/retail, nuclear, compounding and institutional), hospital systems, and outsourcing facilities, consistently seek her out to provide industry-tailored regulatory advice for innovative business models and technological platforms.

Rachael has notable strength in representing health care facilities in high-stakes Federal Food and Drug Administration, (FDA), Drug Enforcement Administration (DEA), and state agency investigations and related litigation, as well as acting as regulatory counsel for large-scale, high-profile transactions involving major healthcare players in the compounding space. Widely regarded as a thought leader on current issues facing the compounding sector, Rachael is called upon to represent coalitions of compounding pharmacies and outsourcing facilities to challenge FDA, state regulators, or other regulatory bodies on critical issues defining the industry. A recognized national authority, Rachael is the leading health care partner in our Chambers-ranked Illinois Health Care group, and is personally ranked by Chambers USA in Band 1 for the Illinois Healthcare: Pharmaceutical/Medical Products Regulatory category. Clients describe her as “quick to understand and support the perspective of the business, allowing her to help formulate business solutions that fit into the regulatory framework of our industry” and say “[h]er intellect, measured responses, written expertise and work ethic are unsurpassed."